2024
Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis
Barsotti G, Luciano R, Kumar A, Meliambro K, Kakade V, Tokita J, Naik A, Fu J, Peck E, Pell J, Reghuvaran A, Tanvir E, Patel P, Zhang W, Li F, Moeckel G, Perincheri S, Cantley L, Moledina D, Wilson F, He J, Menon M. Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis. Kidney International Reports 2024, 9: 1354-1368. PMID: 38707807, PMCID: PMC11068976, DOI: 10.1016/j.ekir.2024.02.006.Peer-Reviewed Original ResearchMinimal change diseaseRandomized controlled trialsSafety of metforminDouble-blindPodocyte injuryAdjunctive therapyPlacebo-controlled randomized controlled trialsPhase III studyPhase II trialPrimary glomerular diseaseFocal segmental glomerulosclerosisEffect of metforminPhase IIPlacebo-controlledPreclinical dataNovel urineChange diseaseTissue markersRandomized trialsSegmental glomerulosclerosisGlomerular diseaseMechanistic biomarkersObservational studyFSGSInexpensive agent
2019
Medication-Associated Glomerular Disease
Tucker B, Luciano R. Medication-Associated Glomerular Disease. 2019, 735-772. DOI: 10.1007/978-3-319-49379-4_46.Peer-Reviewed Original ResearchGlomerular diseaseTubule-interstitial diseaseMinimal change diseaseFocal segmental glomerulosclerosisKidney injuryThrombotic microangiopathyAcute hemodynamicsCrystalline nephropathyChange diseaseHistologic patternSegmental glomerulosclerosisAdditional interventionsMedicationsDisease severitySpecific drugsDiseaseInjuryDrugsVasculitisHematuriaMicroangiopathyProteinuriaDiscontinuationGlomerulonephritisNephropathy
2018
Drug-Induced Acute Kidney Injury
Luciano R, Perazella M. Drug-Induced Acute Kidney Injury. 2018, 145-163. DOI: 10.1007/978-1-4939-8628-6_9.Peer-Reviewed Original ResearchDrug-induced acute kidney injuryAcute kidney injuryKidney injuryAcute tubular injury/necrosisAcute interstitial nephritisFocal segmental glomerulosclerosisDrugs/substancesOsmotic nephropathyRisk patientsInterstitial nephritisKidney functionPrescribed medicationsSegmental glomerulosclerosisEarly identificationRenal compartmentsInjuryHarmful drugsTherapeutic agentsAdverse effectsCommon formDrugsMedicationsKidneyCommon problemDiagnostic agents
2017
Medication-Associated Glomerular Disease
Tucker B, Luciano R. Medication-Associated Glomerular Disease. 2017, 1-36. DOI: 10.1007/978-3-319-27334-1_46-1.Peer-Reviewed Original ResearchGlomerular diseaseTubule-interstitial diseaseMinimal change diseaseFocal segmental glomerulosclerosisKidney injuryThrombotic microangiopathyAcute hemodynamicsCrystalline nephropathyChange diseaseHistologic patternSegmental glomerulosclerosisAdditional interventionsMedicationsDisease severitySpecific drugsDiseaseInjuryDrugsVasculitisHematuriaMicroangiopathyProteinuriaDiscontinuationGlomerulonephritisNephropathy